Post_template - OncoOne

Publication: Optimizing Anti-oxMIF Antibodies for Better Therapeutics – MDPI Antibodies

We’re delighted to announce OncoOne’s latest publication in MDPI Antibodies! In our latest publication, we explore how combining in silico tools with experimental validation can enhance antibody engineering. Focusing on the first-generation anti-oxMIF antibody, imalumab, we uncovered surface hydrophobicity and aggregation as key factors limiting

43rd JPM Healthcare Conference 2025, 13 – 16 Jannuary 2025, San Francisco, California, USA

Join OncoOne at #JPM2025 in San Francisco! From January 13-16, 2025, we’ll be at the J.P. Morgan Healthcare Conference, the premier event for biotech, pharma, and investors. Meet our CEO Randolf Kerschbaumer and CSO Michael Thiele in person to explore our oxMIF-targeting antibodies for cancer

CHI Pep Talk, January 13-16, 2025, San Diego, CA, US

We’re excited to announce that our CSO, Michael Thiele, will be presenting at the CHIPepTalk Congress on January 14 at 6 PM in the Targeted Radioligand Therapies stream. Don’t miss this opportunity to hear about our innovative Radioimmunotherapy PreTarg-it® platform, which leverages bispecific antibodies for

LSX Investival Showcase, November 18, 2024, London, UK

We’re excited for the Investival Showcase on November 18 in London! Connect with OncoOne’s CEO, Randolf Kerschbaumer, to learn about our oxMIF-targeting antibodies for inflammation and cancer, and the PreTarg-it® platform for targeted radiotherapy. Schedule a meeting via the conference platform: https://informaconnect.com/investival-showcase/ Let’s explore partnering

BioEUROPE, November 4–6, 2024, Stockholm, SE

Mark your calendars for BIOEurope in Stockholm, November 4–6, 2024! Schedule a one-on-one meeting with OncoOne’s CEO, Randolf Kerschbaumer, and CSO, Michael Thiele to learn about our oxMIF-targeting antibodies for inflammation and oncology, and the PreTarg-it® platform for targeted radiotherapy. Explore exciting partnering opportunities with

Publication: Imperial College London and OncoOne Unveil Latest Findings on ON104 Efficacy in Nephritis in PLoS One

We are delighted to present our latest findings in PLOS ONE, which highlight the therapeutic potential of our anti-oxMIF antibody ON104 in kidney disease! Our findings spotlight the exciting potential of targeting oxMIF in inflammatory kidney diseases. In a rat model of crescentic glomerulonephritis (CGN),

Festival of Biologics, October 15-17, 2024, Basel, CH

Are you attending the FestivalOfBiologics in Basel? Don’t miss our CSO, Michael Thiele, presenting “ON104: Pioneering Treatment for oxMIF-Driven Autoimmune Diseases”. It’s a fantastic opportunity to explore the potential of our lead candidate, the anti-oxMIF antibody ON104, as an innovative treatment for autoimmune conditions. Get

Krebsforschungslauf , October 5, 2024, Vienna, AT

Krebsforschungslauf 2024 – This year, we laced up for the first time, running with heart and purpose to support the fight against cancer! On October 5th, the Uni Campus Altes AKH turned into a vibrant running arena for a great cause. With the goal of

OncoOne’s PreTarg-it® Platform shines on the cover of Molecular Cancer Therapeutics

OncoOne’s PreTarg-it® Platform shines on the cover of Molecular Cancer Therapeutics! Our platform for pre-targeted radioimmunotherapy is featured as the First Disclosure and cover story in this month’s AACR journal Molecular Cancer Therapeutics (MCT). Our innovative two-step regimen is set to revolutionize the delivery of

Bio Asia Taiwan, July 24-28, 2024, Taipei Nangang

Bio Asia-Taiwan is about to start! Don’t miss the chance to schedule a one-on-one meeting with OncoOne’s VP of CMC, Friedmund Bachmann. Attend his talk, “Decoding CMC Program Design: Unveiling the Blueprint for Success in Biologics Development,” on July 25, from 12.30 to 12:50 in